Documented in the literature are insulin resistance and impaired glucose tolerance, fluid retention with edema, joint pain, and carpal-tunnel-type paraesthesias
[7] In parallel, Merck developed MK-677 (ibutamoren), a non-peptide oral GH secretagogue acting through the same receptor, demonstrating that small molecules could also activate this pathway
Behavioral tests, including the rotarod test, assessed the motor coordination and neuromuscular function, and revealed significant improvements in the Curcumin-PLGA nanoparticles + LIFU group, compared to those treated with Curcumin-PLGA nanoparticles alone, LIFU alone, or untreated PD model mice
Philp D et al
The heart rate increase is a pharmacological effect, not a pathological one